title: Successful treatment of refractory adult onset Still's disease with rituximab.
abstract: Adult-onset Still's disease (AOSD) is an uncommon inflammatory condition of unknown origin. In chronic disease, joint involvement is often predominant and erosions are noted in one third of patients. Therapeutic strategies derive from observational data. Corticosteroids are usually the first-line treatment. With inadequate response to corticosteroids, methotrexate appears the best choice to control disease activity and allow for tapering of steroid use. For refractory disease, biological therapy seems the most promising. We report here the case of a 38-year-old female patient with AOSD refractory to cytotoxic agents, treated by rituximab infusion therapy with favorable outcome.
authors.affiliation: Department of Internal Medicine, University Hospital of La Rabta, Tunis. belfeki.nabil@gmail.com.
authors.forename: N
authors.initials: N
authors.lastname: Belfeki
authors.forename: M
authors.initials: M
authors.lastname: Smiti Khanfir
authors.forename: F
authors.initials: F
authors.lastname: Said
authors.forename: A
authors.initials: A
authors.lastname: Hamzaoui
authors.forename: T
authors.initials: T
authors.lastname: Ben Salem
authors.forename: I
authors.initials: I
authors.lastname: Ben Ghorbel
authors.forename: M
authors.initials: M
authors.lastname: Lamloum
authors.forename: M H
authors.initials: MH
authors.lastname: Houman
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069283:Rituximab / Q000627:therapeutic use*; D016706:Still's Disease, Adult-Onset / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D000069283:Rituximab